Ginsenosides, the active compounds found in ginseng, have been traditionally used in East Asian medicine for various health conditions, including cardiovascular health. In recent decades, scientific research has investigated their effects on cardiovascular disease (CVD). Laboratory and animal studies have demonstrated that certain ginsenosides may exert cardioprotective effects by mechanisms such as antioxidant activity, anti-inflammatory effects, improving endothelial function, reducing platelet aggregation, and regulating lipid metabolism. For example, ginsenoside Rb1 and Rg1 have shown potential in improving cardiac function and reducing myocardial injury in preclinical models.

However, despite promising preclinical data, human clinical trials are limited and often of small scale, short duration, or lacking rigorous design. Some studies suggest possible benefits, such as improved blood pressure, lipid profiles, or endothelial function in people at risk for CVD, but these findings are inconsistent and not sufficient for strong clinical recommendations. No major clinical guidelines currently endorse ginsenosides for the prevention or treatment of cardiovascular disease. Overall, while there is a scientific basis for further investigation, the evidence supporting the use of ginsenosides for CVD in humans remains preliminary and modest.